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Thrombolytic therapy is associated with a bleeding tendency that 
may be exacerbated by adjunctive antiplatelet agents. The effect of 
recombinant tissue·type plasminogen activator (rt·PA) alone or in 
combination with aspirin on serial measurements of template 
bleeding time, ex vivo platelet aggregation and coagulation factors 
and the frequency of bleeding was studied in dogs. During infusion 
of rt·PA (15, 30 or 60 Ilg/kg per min for 90 min), a dose·related 
increase in bleeding time was observed. 
In a randomized blinded study of 25 dogs, the baseline bleeding 
time (mean ± SD) was 3.5 ± 1 min in control animals and 4 ± 
2 min after oral aspirin (15 mg/kg body weight). Infusion of rt·PA 
(15 p.g/kg per min for 90 min) prolonged the bleeding time to a 
maximum of 15 ± 12 min. In contrast, combined aspirin and 
rt·PA therapy produced an increase to >30 min during infusion, 
reverting to 13 ± 10 min within 2 h after cessation of infusion. 
Thrombolytic therapy has become an established method for 
treating coronary artery thrombosis in patients with acute 
myocardial infarction (1). Intravenous infusion of recombi· 
nant tissue-type plasminogen activator (rt-PA) recanalizes 
occluded coronary arteries (2-4), preserves left ventricular 
function (5-7) and reduces mortality (7). Adjunctive therapy 
with aspirin has also been shown to further improve survival 
after administration of streptokinase (8). 
The major side effect of thrombolytic therapy is bleeding, 
which on occasion may be life-threatening. Concern has 
focused on the frequency of intracranial bleeding, which 
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Recurrent continuous bleeding from incision sites occurred in one 
of six dogs given aspirin alone, two of seven given rt·PA alone and 
all six dogs given both aspirin and rt·PA (p = 0.02). Bleeding time 
>9 min correlated significantly with bleeding frequency (p < 
0.0001), with a sensitivity of 100% and a specificity of 87%. 
Intravenous bolus injection of aprotinin (20,000 kallikrein 
inhibitor units/kg body weight) in six dogs given both rt·PA and 
aspirin produced a decrease in bleeding time from >30 min to 9.5 
± 9 min and resulted in cessation of bleeding. Thus, bleeding and 
bleeding time prolongation in this canine model are potentiated by 
a marked interactive effect of rt·PA and aspirin that is rapidly 
reversible. Template bleeding times may provide a useful quanti. 
tative index for monitoring the bleeding tendency associated with 
thrombolytic therapy. 
(J Am Coli CardioI1991;17:1213-22) 
although not observed in the initial studies with rt-PA (2-4), 
has occurred subsequently in as many as 1.6% of treated 
patients (6,9). More recently, administration of rt-PA at the 
currently recommended 100 mg dose has established an 
intracranial bleeding frequency of 0.5% (10) and 0.1% excess 
stroke rate relative to patients not treated with thrombolytic 
agents (7). Available comparative trials of streptokinase and 
rt-PA indicate that hemorrhagic complications do not corre-
late strictly with the extent of fibrinogen breakdown pro-
duced by thrombolytic therapy (3,4,11,12). Thus, although 
its pathogenesis is not established, bleeding associated with 
thrombolytic therapy seems to result not from disturbance of 
the hemostatic system, but from vascular injury (13) and 
possibly from interference of the thrombolytic agent with 
hemostatic plug formation. 
On the basis of the latter hypothesis, we postulated that 
measurement of laboratory variables in vivo may provide a 
reliable marker for monitoring hemorrhagic risk during 
thrombolytic therapy. In a recent pilot study (14), significant 
prolongation of bleeding time that correlated with the occur-
rence of spontaneous bleeding was observed during infusion 
ofrt-PA in patients with acute myocardial infarction. 
The present investigation was designed to extend these 
observations by examining the effect of rt-PA administered 
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under controlled experimental conditions alone or in combi-
nation with aspirin on measurements of hemostasis and the 
frequency of bleeding in dogs. The time course and extent of 
changes in template bleeding time, ex vivo platelet aggrega-
tion and coagulation factors were investigated. In a prelim-
inary study, different doses of rt-PA alone and in combina-
tion with aspirin were administered. In the second phase, 
dogs were assigned randomly to treatment with fixed doses 
ofrt-PA or aspirin, both or neither. Investigators performing 
these tests did not know which study drugs had been 
administered. Finally, the reversibility with intravenous 
aprotinin, a serine protease inhibitor, of bleeding time pro-
longation and bleeding after combined therapy with aspirin 
and rt-PA was tested. 
Reagents. Recombinant human tissue-type plasminogen 
activator (rt-PA) (Genentech, Inc.) was provided in vials 
containing 50 mg of lyophilized material in predominantly 
single chain form (Activase). Adenosine 5' -diphosphate 
(ADP) and lyophilized aprotinin were purchased from Sigma 
Chemical Co., and epinephrine and arachidonic acid from 
BioData Corporation; all agents were reconstituted in dis-
tilled water. Aspirin and vitamin tablets were purchased 
from the hospital pharmacy. 
Animal preparation and treatment. Adult mongrel dogs 
weighing 5 to 18 kg were anesthesized with sodium pento-
barbital (30 mg/kg intravenously, followed by 10 mg bolus 
injections as needed), intubated and placed on a mechanical 
respirator. The femoral artery and vein were then cannu-
lated, with local hemostasis controlled by careful vessel 
ligation. No heparin was administered. 
Infusion of rt-PA or placebo was administered at doses 
adjusted to body weight (p,g/kg per min for 90 min) into the 
femoral vein by means of a constant rate infusion pump 
(Harvard Apparatus). Aspirin or placebo tablets were given 
orally 2 to 4 h before induction of anesthesia at the indicated 
doses per kg body weight. Aspirin tablets (80 or 325 mg) 
were administered wholly or in part in a total dose closely 
approximating the indicated dose per kg body weight. Blood 
pressure was monitored from the femoral artery. These 
studies were performed in conformance to the Position of the 
American Heart Association on Research Animal Use 
adopted November 11, 1984. 
Design of the studies. The experimental sequence for 
treatment and measurement of laboratory variables is illus-
trated in Figure 1. 
Phase 1. In the preliminary dose-finding study, 26 dogs 
were allocated to treatment with saline solution (Group I) or 
to 15 (Group II), 30 (Group III) or 60 (Group IV) #kg/kg per 
min of rt-PA for 90 min. Then, in six additional dogs, rt-PA 
infusion at 15 p,g/kg per min for 90 min was administered in 
combination with oral aspirin doses of 10 (Group V), 15 
(Group VI) or 40 or 100 (Group VII) mg/kg body weight. 
Phase 2. The second phase was designed to document 
the effect of combined rt-PA and aspirin therapy on bleeding 
time and frequency of bleeding in a randomized prospective 
study design, with the investigators performing laboratory 
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Figure 1. Schematic representation of the time course of interven-
tion, study drug infusion and analyses. Oral aspirin or placebo 
administration preceded induction of anesthesia by approximately 2 
to 4 h, after which femoral venous and arterial lines were placed and 
baseline bleeding time and blood sampling performed. Infusion of 
recombinant tissue-type plasminogen activator (rt-PA) or placebo 
was then done for the next 90 min, followed by a 2 h observation 
period and final bleeding time determination and blood sampling. 
o = Whole blood samples processed as described in Methods and 
used for ex vivo platelet aggregation and measurement of plasma 
fibrinogen, alpha2-antiplasmin and rt-PA-related antigen levels and 
platelet counts. 'f == intervals at which template bleeding time was 
measured. 
measurements and assessment of bleeding without knowl-
edge ofthe study drugs administered. Twenty-five dogs were 
assigned to one of the following treatments groups: 1) rt-PA 
excipient infusion for 90 min and aspirin placebo (Group I); 
2) 15 #kg/kg per min of rt-PA for 90 min and aspirin placebo 
(Group II); 3) rt-PA excipient and 15 mg/kg of aspirin (Group 
III); or 4) 15 J.tg/kg per min ofrt-PA for 90 min and 15 mg/kg 
of aspirin. 
Phase 3. In the third phase of this study, the efficacy of 
an antifibrinolytic agent in reversing bleeding time prolonga-
tion and bleeding was tested. Six additional dogs treated 
with 15 mg/kg of aspirin and 15 p.g/kg per min of rt-PA for 
90 min were given an intravenous bolus injection of 20,000 
kallikrein inhibitor units (KIU)/kg body weight of reconsti-
tuted, lyophilized aprotinin 60 to 90 min after the start of 
rt-PA infusion. 
Bleeding and template bleeding times. Template bleeding 
times were measured before (usually in duplicate) and 30, 60, 
90 and 210 min after the start of infusion. A spring-activated 
surgical steel blade instrument (Surgicutt International, 
Technidyne Corporation) designed to produce a standard-
ized incision (5 mm long by 1 mm deep) was applied to a 
shaved foreleg. Incisions were performed parallel to and 
below the antecubital crease. Flow of blood from the wound 
was blotted at 30 s intervals with filter paper disks (Whatman 
#5, Whatman International Ltd.), carefully avoiding direct 
contact with the wound. The duration of bleeding was 
quantitated by timing the interval (to the nearest 30 s) from 
incision to cessation of bleeding as demonstrated by no 
further staining of the filter paper. The range of normal 
values for bleeding time in anesthesized dogs established 
previously by our laboratory is from 1 to 9 min. Values 
> 30 min were assigned a 30 min value for purposes of 
statistical analysis. 
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Bleeding documented after the start of infusion was 
defined as the occurrence of renewed spontaneous oozing 
from formerly coagulated bleeding time or femoral incision 
sites. Perturbation of incision wounds was carefully avoided. 
The occurrence of spontaneous bleeding after the start of 
infusion was closely monitored for the duration of each 
experiment. 
Platelet aggregation. Arterial blood samples (10 ml) for ex 
vivo platelet aggregation studies were collected in 0.1 ml of 
40% trisodium citrate containing 500 KIU of reconstituted, 
lyophilized aprotinin/ml of blood to preclude proteolysis in 
vitro. In previous experiments (unpublished observations), 
identical aggregation patterns were obtained in duplicate 
platelet-rich plasma samples with and without addition of 
reconstituted, lyophilized aprotinin. In contrast, use of com-
mercially available aprotinin reconstituted in 0.9% benzyl 
alcohol suppressed the maximal percent change in transmit-
tance (%6T) and caused platelet disaggregation in vitro. 
Samples were obtained before and 45, 90 and 2 IO min after 
the start of infusion. Platelet-rich plasma was prepared by 
centrifugation at 700 g for 3.5 min at 22°C and removal of the 
supernatant with a plastic pipette. The platelet-rich plasma 
was then stored in a capped polystyrene test tube at 22°C, 
and aggregation tests were performed within 3 h. Platelet-
poor plasma was prepared from the remaining blood sample 
by centrifugation at 2,000 g for 8 min at 22°C and removal of 
the supernatant. Platelet counts were determined with an 
automated particle counter (Thrombocounter C, Coulter 
Electronics, Inc.) equipped with a 70 /Lm aperture. Platelet 
concentration in the platelet-rich plasma was first adjusted to 
3 x I08/ml and then 0.4 ml aliquots of platelet-rich plasma 
were aggregated with ADP (7.5 to 20 /LM final concentra-
tion). 
In the randomized blinded study, tests were also per-
formed with arachidonic acid (0.9 /LM final concentration) to 
document blocking of platelet aggregation due to aspirin 
inhibition of cyclooxygenase. Platelet-rich plasma was pre-
treated with epinephrine (0.5 /LM final concentration) for 
30 s at 37°C before addition of arachidonic acid. In the 
absence of aspirin, addition of arachidonic acid always 
produces aggregation of canine platelet-rich plasma if pre-
ceded by epinephrine potentiation, but aggregation does not 
always occur in response to arachidonic acid alone (15). 
Canine platelet-rich plasma does not aggregate with the 
addition of epinephrine alone. All aggregations were per-
formed in a dual channel aggregometer (Chrono-Iog Corpo-
ration) at 37°C with constant stirring at 1,200 rpm. Quanti-
tative analysis of aggregation was determined as the maximal 
percent change in transmittance (%6T) (measured from 
baseline to the lowest portion of the curve) after addition of 
agonist. 
Hemostasis analysis. Arterial blood samples (4.5 ml) for 
measurement of fibrinogen were collected into 0.5 ml of 
trisodium citrate (0.11 M) and 200 KIU of aprotinin/ml of 
blood before and 45, 90 and 2 IO min after the start of 
infusion. Additional samples for measurement of alpha2-
antiplasmin were collected into sodium citrate in the absence 
of aprotinin before and 210 min after the start of infusion. To 
measure the concentration of rt-PA-related antigen in 
plasma, 2 ml blood samples were collected into 0.05 ml 
(15%) liquid ethylenediaminetetraacetate (K3) (EDTA) at 
15 min intervals during infusion and at 210 min after the start 
of infusion. Plasma was separated at 22°C by centrifugation 
at 2,300 g from blood kept on ice until the end of the 
experiment and then stored at - 20°C until assayed. Samples 
were also collected into EDTA immediately before the start 
of infusion for measurement of serum salicylate (16) and 
before and 210 min after the start of infusion for measure-
ment of platelet count. 
Fibrinogen was measured by a modified version (17) of 
the coagulation rate assay of Clauss (18) and expressed as a 
percent of pretreatment values. An enzyme-linked immuno-
sorbent assay based on monoclonal antibodies was used to 
measure the plasma concentration of rt-PA-related antigen 
(19). Alpha2-antiplasmin was assayed using the chromogenic 
substrate S-2251 (KabiVitrum) and expressed in percent by 
comparison with a standard curve obtained by serial dilution 
of a normal plasma pool (20). 
Statistical analysis. Results are expressed as mean values 
± SD. Student's t test for paired or unpaired values was used 
to evaluate two-tailed levels of significance of differences 
within or between groups. A Wilcoxon test was used to 
evaluate differences in cases in which the data were not 
normally distributed. The significance of differences be-
tween groups was analyzed using the Fisher or Kruskal-
Wallis exact test (21). The relation between bleeding time 
and rt-PA dose in the dose-response study was analyzed 
using the lonckheere-Terpstra test (21). The correlation of 
bleeding with prolonged bleeding time or decreased plasma 
fibrinogen concentration was analyzed by stepwise logistic 
regression (BMDP Statistical Software, University of Cali-
fornia-Los Angeles). Variables used in this model were 
bleeding time >9 and ~15 min and fibrinogen concentration 
< I g/liter at 90 min. Two-tailed p values <0.05 were consid-
ered statistically significant. 
Results 
Dose-Response Study 
Template bleeding times. Table 1 summarizes the results 
of serial template bleeding times in the initial group of 26 
dogs. In the control group (Group I), bleeding times were 
within the normal range and remained essentially unchanged 
from baseline values throughout the experiment. Propor-
tional increases were observed in association with infusion 
ofrt-PA at progressively higher doses (Groups II to IV) (p = 
0.003). The increase in bleeding time to a maximum of 11 ± 
IO min during infusion of 15 /Lg/kg per min of rt-PA for 
90 min (Group II) was attributable mainly to a single 30 min 
value. All other bleeding times measured at this infusion rate 
remained ::::;9 min (upper limit of normal). When the rt-PA 
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Table 1. Template Bleeding Times During and After Administration of Recombinant Tissue-Type Plasminogen Activator (rt-PA) and 
Aspirin: Results of the Dose-Response Study 
Protocol Template Bleeding Time (min) 
rt-PA (,ug/kg Aspirin No. of 
Group per min) (mg/kg) Dogs Pre 30 Min 60 Min 90 Min 210 Min 
0 0 3 3.0 ± 2.0 2.0 ± 1.5 2.5 ± 1.0 3.0 ± 2.0 3.0 ± 2.0 
(1.0-5.0) (1.0-3.0) (2.0-3.5) (1.0-5.0) (1.0-5.0) 
II 15 0 6 3.5 ± 1.0 5.0 ± 1.5 l1±\O 5.5 ± 1.5 5.5 ± 1.5 
(2.0-5.0) (2.5-7.5) (5.0-30) (3.0-7.5) (4.0-8.0) 
III 30 0 6 4.5 ± 2.5 \0 ± 7.0 12 ± 9.0 14 ± 9.0 \0 ± 9.0 
(2.0-9.0) (3.5-20) (6.0-30) (7.0-30) (2.0-25) 
IV 60 0 5 3.5 ± 3.0 6.5 ± 6.5 15 ± \0 22 ± 9.0 6.0 ± 5.0 
(1.0-8.5) (3.0-18) (2.0-30) (9.0-30) (1.0-11) 
V 15 \0 2 8.0 ± 0.4 14 ± 4.0 21 ± 13 \3 ± 9.0 5.5 ± 2.0 
(7.5-8) (11-17) (12-30) (6-19) (4-7) 
VI 15 15 2 6.0 ± 1.5 \O±1.5 30 30 15 ± 3.5 
(5-7) (9-11) (30) (30) (12-17) 
VII 15 40 or 2 5 29 ± 1.5 30 25 ± 8 19 
100 (5) (28-30) (30) (19-30) (19) 
Data are mean values ± SD and (range) at time points before and after the start ofrt-PA infusion. Group I = dogs given saline solution; Groups II to IV = 
dogs treated with 15, 30 or 60 JLg/kg per min, respectively, of rt-PA infusion for 90 min; Groups V to VII = dogs treated with rt-PA infusion at 15 JLg/kg per min 
plus oral aspirin in doses of \0 (Group V), 15 (Group VI) or 40 or 100 (Group VII) mg/kg body weight. Pre = before rt-PA administration. 
dose was doubled (Group III), more frequent prolongation of 
the bleeding time was observed, with values >9 min ob-
tained in three dogs during infusion (maximum of > 30 min in 
two), which normalized 2 h after the end of the infusion in 
two of these dogs. A fourfold rt-PA dosage increase (Group 
IV) produced a maximal bleeding time of 22 ± 9 min, with 
peak values >9 min (>30 min in one dog) observed in all 
dogs, reverting to <9 min within 2 h after the end of infusion 
in all but one dog. 
In aspirin{ree dogs (Groups I to IV), serum salicylate 
concentration measured 8 ± 18 JLg/ml and the bleeding time 
before start of infusion averaged 3.5 ± 2 min. Four hours 
after ingestion of 10 (Group V) or 15 (Group VI) mg/kg of 
aspirin, salicylate levels increased to 50 ± 20 and 47 ± 
3.5 JLg/ml, respectively, and baseline bleeding times were 
modestly but significantly prolonged (p < 0.01 versus aspi-
rin-free dogs). During infusion of 15 JLg/kg per min of rt-PA 
for 90 min, marked prolongation of bleeding time to >30 min 
was obtained in three of these four aspirin-treated dogs. In 
the remaining dog given 10 mg/kg of aspirin, the maximal 
bleeding time during infusion was 12 min in association with 
the lowest salicylate level (36 JLg/mi) in aspirin-treated dogs. 
At the end of infusion, the bleeding time in both dogs given 
15 mg/kg of aspirin remained> 30 min, whereas in the two 
dogs receiving 10 mg/kg of aspirin, these values measured 6 
and 19 min. Within the next 2 h, the average bleeding time 
decreased by approximately 50% in both groups. 
Serum salicylate levels were 97 and 200 JLg/ml in two dogs 
given a higher dose of aspirin of 40 or 100 mg/kg (Group VII), 
respectively. During rt-PA infusion, the bleeding time pro-
longed to > 30 min, remaining >9 min in both dogs at the end 
of the observation period. 
The serum salicylate level measured after a dose of 
10 mg/kg of aspirin demonstrated a large standard deviation 
and was lowest in the only nonresponsive (maximal bleeding 
time of 12 min with no observed bleeding) dog from the 
initial combined therapy groups. These findings suggested 
the possibility that blood levels of aspirin sufficient for 
complete cyclooxygenase inhibition may not be produced 
consistently with this dose in all dogs. Accordingly, a 
slightly higher aspirin dosage (15 mg/kg) was selected for use 
in the second and third phases of this study. 
Bleeding and bleeding time prolongation. No bleeding 
was observed from femoral or bleeding time incision sites in 
any dog before the start of the infusion. There was no 
bleeding in control dogs (Group I). Of the nine dogs with a 
maximal bleeding time >9 min during administration of 
rt-PA alone, bleeding, which always persisted for> 10 min, 
was observed in five (one in Group II and two in each of 
Groups III and IV). No bleeding was observed in the eight 
dogs with a bleeding time :59 min during rt-PA infusion 
alone. Bleeding that always persisted> 10 min was observed 
in five of six dogs in the combined therapy groups (Groups V 
to VII), all with a maximal bleeding time> 30 min. The one 
dog with no bleeding received 10 mg/kg of aspirin and 
demonstrated a peak bleeding time of 12 min. 
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Table 2. Platelet Aggregation and Hemostasis Variables After Administration of Recombinant Tissue-Type Plasminogen Activator (rt-PA) 
and Aspirin: Results of the Dose-Response Study 
Alpha2-
Platelet Aggregation (%11 T) Plasma rt-PA (~g!ml) Fibrinogen (g/liter) Antiplasmin (%) 
Group Pre 90 Min 210 Min 30 Min 60 Min 90 Min 210 Min Pre 90 Min 210 Min Pre 210 Min 
60 ± 21 70 ± 20 55 ± 5 1.8 ± 0.1 1.5 ± 0.1 1.6 ± 0.1 76 ± 7 71 ± 8 
(38-80) (50-79) (50-60) 
II 55 ± 18 64 ± 15 56 ± 35 0.6 ± 0.1 0.8 ± 0.2 0.9 ± OJ 0.08 ± 0.03 2.2 ± 1.0 1.1 ± 0.5 1.2 ± 0.7 79 ± 13 40 ± 20 
(28-73) (35-75) (13-106) 
III 66 ± 9 56 ± 8 59 ± 18 1.1 ± 0.4 1.8 ± 0.6 1.6 ± 0.9 OJ ± OJ \,7 ± 0.5 \.0 ± 0.5 1.2 ± 0.7 81 ± 10 25 ± 8 
(50-76) (46-68) (34-73) 
IV 58 ± 18 35 ± 28 34 ± 35 4.6 ± 1.5 5.4 ± 3.4 6.4 ± 5.6 0.4 ± OJ \.9 ± 0.6 OJ ± OJ 0.19 ± 0.12 80 ± 17 14 ± 6 
(38-75) (0-69) (5-81) 
V 99 ± 1 70 ± 42 70 ± 53 0.7 ± 0.4 1.0 ± 0.7 1.2 ± 0.8 0.06 ± 0.02 3.2 ± 0.5 1.1 ± 1.6 1.4 ± 2.0 80 ± 5 38 ± 25 
(98-100) (40-100) (33-106) 
VI 73 ± 5 75 ± 4 75 ± 9 0.7 ± 0.14 0.8 ± 0.07 0.8 ± 0.07 0.05 ± om 3J ± 0.8 2.8 ± 1.3 2.7 ± 1.1 97 ± 19 62 ± 29 
(69-75) (73-78) (69-81) 
VII 55 ± 2 41 ± 39 48 ± 35 1.1 ± 0.4 1.4 ± 0.4 1.5 ± 0.4 0.09 ± 0.02 \.9 ± 0.2 0.6 ± 0.7 0.5 ± 0.7 74 ± 16 31 ± 8 
(53-56) (14-69) (23-73) 
Data are mean values ± SD and (range). %I1T = maximal percent change in transmittance. 
The frequency of bleeding was related significantly to 
prolongation of the bleeding time to >9 min (p < 0.0001), 
yielding a sensitivity and specificity of 100% and 69%, 
respectively. In dogs given rt-PA alone, bleeding was not 
related significantly to the dose of rt-PA (p = 0.29). 
Platelet aggregation and hemostasis. Table 2 shows re-
sults of ex vivo platelet aggregation tests and hemostasis 
analysis. Substantial (40%) diminution of ADP-induced 
platelet aggregation from the baseline value was observed 
concomitantly with plasma fibrinogen depletion at the end of 
the highest rt-PA infusion (Group IV) and persisted for the 
next 2 h. During this interval, however, the qleeding time 
shortened from 22 ± 9 to 6 ± 5 min. In all other treatment 
groups, the extent of aggregation with ADP remained essen-
tially unchanged from baseline values during the experiment. 
No discrete secondary wave of aggregation was observed in 
dogs that received aspirin. 
Systemic fibrinolytic activation characterized by con-
sumption of alpha2-antiplasmin and fibrinogen breakdown 
was observed in all groups treated with rt-PA (Table 2). 
These changes and plasma levels of rt-PA were generally 
proportional to the rate of infusion. Maximal effects were 
again observed at an infusion rate of 60 JLg/kg per min 
for 90 min, yielding plateau levels of rt-PA in plasma of 
>5 JLg/ml and an intense systemic fibrinolytic state charac-
terized by alpha2-antiplasmin depletion to 14 ± 6% and 
fibrinogen degradation to 0.19 ± 0.12 glliter. Administration 
of aspirin did not significantly change the effect of an rt-PA 
infusion at 15 JLg/kg per min for 90 min on hemostatic 
variables. Platelet counts remained unchanged in all groups 
at mean values between 250,000 and 350,000/mm3• 
Randomized Blinded Study 
To preclude the influence of technical variability and 
subjective analysis in performance of bleeding time measure-
ments and classification of bleeding, a prospective blinded 
study in which 26 dogs were randomized to receive either 
aspirin (15 mg/kg), rt-PA (15 JLg/kg per min for 90 min), both 
or neither was performed. One dog was excluded because of 
technical failure in performance of template bleeding times. 
The remaining 25 dogs form the study group. 
Template bleeding times. Table 3 summarizes the results 
of serial template bleeding times in the four randomized 
groups. In control dogs (Group I) given rt-PA excipient 
infusion and aspirin placebo, bleeding time remained essen-
tially unchanged from baseline values throughout the exper-
iment and all values were within the normal range. Infusion 
of rt-PA alone (Group II) resulted in moderate prolongation 
of bleeding time to a maximum of 15 ± 12 min (p = 0.01). Of 
four dogs demonstrating values >9 min during infusion, the 
value was> 30 min in two. Within the next 2 h, the bleeding 
time normalized to 8.0 ± 5.5 min, but values >9 min were 
still observed in three dogs. Aspirin administration (Group 
III) produced minor nonsignificant prolongation of baseline 
bleeding time in comparison with the control group, which 
remained unchanged during and after infusion of rt-PA 
placebo. Only a single value >9 min was observed in this 
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Table 3. Template Bleeding Times and Bleeding After Administration of Recombinant Tissue-Type Plasminogen Activator (rt-PA) and 
Aspirin: Results of the Randomized Study 
Protocol 
rt-PA Aspirin No. of 
Group (JLg/kg per min) (mg/kg) Dogs Pre 
0 0 6 3.5 ± 1.0 
(2.5-6.0) 
II 15 0 7 4.5 ± 2.5 
(2.5-8.0) 
III 0 15 6 4.0 ± 2.0 
(2.0-7.0) 
IV 15 15 6 5.5 ± 2.0 
(2.5-7.5) 
Data are mean values ± SD and (range). 
group. In the aspirinlrt-PA combination treatment group 
(Group IV), the bleeding time increased to >30 min in all 
dogs at 60 and 90 min after the start of infusion. Two hours 
after completion of rt-PA infusion, the bleeding time re-
verted to 13 ± 10 min, with values >9 min in only two dogs. 
Bleeding and treatment. Bleeding was not observed from 
femoral or template bleeding time incision sites in any dog 
before the start of infusion. In placebo-treated dogs (Group 
I), no bleeding was documented. One dog in the aspirin 
group (Group III) demonstrated slight oozing throughout the 
experiment from the femoral catheterization site in associa-
tion with a maximal bleeding time of 9 min. In the rt-PA 
group (Group II), bleeding was observed in two of seven 
dogs. In one dog, bleeding from the catheterization and 
preinfusion bleeding time incision sites started between 45 
and 60 min after the start of rt-PA infusion and continued 
throughout the experiment. In this dog, the bleeding time 
was 22 min at the end of infusion and shortened only to 
18 min at the end of the observation period (210 min) in 
association with a plasma fibrinogen level of 0.13 g/liter. In 
the remaining dog, oozing from the preinfusion bleeding time 
incision wound occurred during the infusion, but stopped 
within 30 min after the end of rt-PA therapy. 
In the combined aspirin and rt-PA treatment group 
(Group IV), bleeding from the catheterization and preinfu-
sion bleeding time wounds was observed in all dogs. It began 
within 15 min after the start of the infusion in three dogs, 
within 45 min in one dog and within 60 min in two dogs and 
persisted for the duration of infusion. Continued oozing 
throughout the experiment occurred in one dog in which the 
bleeding time remained > 30 min and circulating fibrinogen 
decreased to an unmeasurable level. In all other dogs, 
bleeding stopped during the observation period after cessa-
tion of the rt-PA infusion. 
The frequency of bleeding in the randomized study was 
not significantly increased in dogs given aspirin (Group lll) 
(p > 0.5) or rt-PA (Group II) alone (p = 0.46) in comparison 
Template Bleeding Time (min) 
30 Min 60 Min 90 Min 2\0 Min 
4.5 ± 2.0 4.0 ± 1.5 3.5 ± 1.5 4.0 ± 2.5 
(3.5-7.5) (2.5-6.0) (1.5-5.5) (1.5-7.0) 
14 ± 12 15 ± 12 12 ± II 8.0 ± 5.5 
(3.0-30) (3.0-30) (3.0-22) (3.0-18) 
5.0 ± 4.0 5.5 ± 3.5 4.0 ± 3.0 4.0 ± 2.5 
(1.0-12) (1.5-11) (2.0-9.0) (2.0-8.5) 
29 ± 2.0 30 30 13±\O 
(25-30) (30) (30) (6-30) 
with the placebo group (Group I). In contrast, dogs treated 
with both aspirin and rt-PA demonstrated a significantly 
greater frequency of bleeding than those receiving rt-PA 
alone (p = 0.02). Although small but significant effects of 
aspirin or rt-PA alone on bleeding may have been missed as 
a result of the small sample size, these findings indicate that 
the interactive effect of aspirin and rt-PA was the most 
important determinant of bleeding. 
Platelet aggregation and hemostasis (Table 4). No sub-
stantial variations in the extent of ADP-induced aggregation 
from baseline measurements were detected during the ex-
periment in any treatment group. Epinephrine-potentiated, 
arachidonic acid-induced platelet aggregation performed im-
mediately before the start of infusion was abolished in all 
dogs given aspirin (Groups III and IV), documenting cyclo-
oxygenase inhibition. A discrete secondary phase of aggre-
gation was also not detected in these dogs. Plasma levels of 
rt-PA, fibrinogen and alpha2-antiplasmin were comparable 
with results obtained in the corresponding groups during the 
initial dose-response study. Platelet counts did not change 
significantly in any of the groups. 
Correlation of bleeding time with bleeding frequency or 
treatment. Table 5 summarizes the observed relation be-
tween bleeding and the longest template bleeding time mea-
sured (at 60 or 90 min) after the start of the infusion. 
Bleeding, which occurred in 9 of 25 dogs, correlated signif-
icantly with prolongation of the bleeding time to >9 min (p < 
0.0001), thereby predicting bleeding with a sensitivity of 
100% (9 of 9 dogs) and a specificity of 87% (14 of 16 dogs). 
No statistically significant relation was observed between 
prolongation of bleeding time and therapy in the aspirin and 
placebo groups. This relation was marginally significant in 
the rt-PA-treated dogs in comparison with placebo-treated 
dogs (p = 0.04). In contrast, the bleeding time demonstrated 
significant prolongation when rt-PA was combined with 
aspirin as compared with placebo treatment (p < 0.0001). 
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Table 4. Platelet Aggregation and Hemostasis Variables Mter Administration of Recombinant Tissue-Type Plasminogen Activator (rt-PA) 
and Aspirin: Results of the Randomized Study 
EPI-AA Serum 
Aggregation Alpha2- Salicylate 
ADP Aggregation (%i1T) (%i1T) Plasma rt -P A (I'g!ml) Fibrinogen (g!Hter) Antiplasmin (%) (~m1) 
Group Pre 90 Min 210 Min Pre 30 Min 60 Min 90 Min 210 Min Pre 90 Min 210 Min Pre 210 Min Pre 
91 ± 18 85 ± 16 83 ± 16 83 ± 24 2.8 ± 1.4 2.6 ± 1.2 2.5 ± \.3 73 ± 14 72 ± 12 19 ± Jl 
(75-113) (61-106) (69-113) (63-113) / 
II 88 ± 16 85 ± 15 89 ± 16 89 ± 14 0.7 ± 0.2 0.8 ± 0.4 0.8 ± 0.4 0.06 ± 0.02 2.5 ± 1.0 1.6 ± 1.2 2.1 ± 1.6 67 ± 7 30 ± 11 19 ± 13 
(60-105) (75-113) (65-113) (69-106) 
III 79 ± 13 83 ± 14 84 ± 18 0 3.1 ± 1.6 3.1 ± 1.6 3.1 ± 1.7 70 ± 9 65 ± 13 61 ± 9 
(64-93) (70-109) (70-113) 
IV 79 ± 1J 63 ± 31 66 ± 25 0 0.8 ± OJ 0.9 ± 0.4 0.9 ± 0.5 0.09 ± 0.06 3.0 ± 1.1 1.8 ± 1.0 1.9 ± 1.2 72 ± 8 38 ± 21 55 ± 12 
(70-98) (10-94) (16-84) 
Data are mean values ± SD and (range). ADP = adenosine 5'-diphosphate; EPI-AA = epinephrine and arachidonic acid; %i1T = maximal percent change 
in transmittance. 
Combined study groups. Corresponding data from the 
dose-response and randomized blinded studies were pooled 
and statistical analysis performed, yielding significance lev-
els identical to results presented in Table 4. Prolongation of 
the bleeding time to >9 min predicted bleeding with a 
sensitivity of 100% (19 of 19 dogs) and a specificity of 78% 
(25 of 32 dogs). 
Persistent bleeding after cessation of the rt-PA infusion 
in association with a prolonged bleeding time and plasma 
fibrinogen depletion was observed in two dogs in the ran-
domized study. To determine the relation between de-
creased plasma fibrinogen concentration and bleeding time 
prolongation with the occurrence of bleeding, stepwise lo-
gistic regression of bleeding versus fibrinogen concentration 
at 90 min « 1 g/liter) and versus bleeding time (>9 and 
~15 min) was performed for all dogs. This analysis indicated 
that bleeding time was by far (p < 0.0001) the strongest 
predictor of bleeding. Although decreased fibrinogen level 
Table S. Correlation of Bleeding Time With Bleeding and 
Treatment in 25 Dogs in the Randomized Blinded Study 
Bleeding Time (min) 
s9 10-14 15-29 >30 p Value 
Bleeding vs. 0 0 8 <0.0001 
No bleeding 14 1 0 
Aspirin vs. 5 0 0 >0.1 
Placebo 6 0 0 0 
rt-PA vs. 1 2 0.04 
Placebo 6 0 0 0 
Aspirin + rt-PA vs. 0 0 0 6 <0.0001 
Placebo 6 0 0 0 
rt-PA = recombinant tissue-type plasminogen activator. 
was also related to bleeding (p < 0.02), in our logistic 
regression model that included bleeding time, this measure-
ment added no significant predictive value (p == 0.78). In a 
smaller sample size of dogs receiving rt-PA alone (Groups II, 
III and IV in the dose-finding study and Group II in the 
randomized study), bleeding time was also the strongest 
predictor of bleeding (p == 0.01). Fibrinogen values added no 
significant predictive value in a model that included bleeding 
time (p == 0.28). 
Reversal of bleeding and bleeding time prolongation with 
aprotinin. Intravenous bolus administration of 20,000 KIU 
of aprotinin/kg body weight was tested in six additional dogs 
given 15 mg/kg of aspirin and 15 ILg/kg per min of rt-PA for 
90 min. In these dogs, epinephrine-potentiated, arachidonic 
acid-induced platelet aggregation was abolished. The maxi-
mal percent change in transmittance (%~T) of ADP-induced 
aggregation, which produced only a single wave, was 78 ± 
9% before rt-PA infusion and 71 ± 11% and 70 ± 35% at 90 
and 210 min, respectively. Plasma rt-PA levels increased to 
1.0 ± 0.4 ILg/ml at 30 min, plateaued at 1.1 ± 0.4 ILg/ml at 
60 min and declined to 0.1 ± 0.04 ILg/ml at 210 min. Plasma 
fibrinogen concentration was 1.9 ± 0.5 g/liter before infusion 
of rt-PA, 1.1 ± 0.7 g/liter at 90 min and 1.3 ± 0.7 g/liter at 
210 min. Levels of alpha2-antiplasmin were 62 ± 7% before 
infusion, decreasing to 48 ± 12% at 210 min. Administration 
of aprotinin 60 to 90 min after the start of rt-PA infusion 
resulted in abrupt and marked shortening of the bleeding 
time from > 30 min in all dogs to :59 min in five dogs 
measured 2 min after injection (Fig. 2). In addition, bleeding 
in five dogs stopped within 10 min after aprotinin injection. 
In the remaining dog, persistent oozing from incisions made 
after the start of infusion occurred in association with a 
bleeding time of 21 min at 90 min, which decreased to 9 min 
at the end of the experiment; the plasma fibrinogen concen-
tration was unmeasurable in this dog. 
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Figure 2. In six dogs treated with the combination of 15 mg/kg of 
aspirin and 15 ,ug/kg per min of recombinant tissue-type plasmino-
gen activator (rt-PA) for 90 min, a bolus injection of 20,000 KIU of 
aprotininlkg body weight was given after bleeding time prolonged to 
> 30 min in all dogs. The abrupt and marked decrease in bleeding 
time observed after this treatment was accompanied by cessation of 
bleeding. Results are expressed as mean ± standard deviation 
obtained at times indicated after the start of rt-PA infusion. 
Discussion 
Rationale of the study. The main objective of this study 
was to examine the effect of recombinant tissue-type plas-
minogen activator (rt-PA) administered under controlled 
experimental conditions alone or in combination with aspirin 
on measurements of hemostasis and determine whether 
template bleeding time measurements correlate with the 
observed hemorrhagic tendency. Although a relation be-
tween bleeding time prolongation and recent aspirin inges-
tion with the frequency of spontaneous bleeding was ob-
served previously (14) in a pilot study in patients given 
rt-PA, the preliminary nature and retrospective design of 
that study provided the rationale for the current prospective 
study. 
The selection of dogs for these experiments was based on 
the extensive use of this species in preclinical studies of 
coronary arterial thrombolysis (22) and adjunctive therapy 
(23). As background for future investigations on the relative 
fibrinolytic potency and hemostatic effects of new agents or 
combinations for thrombolytic therapy, the necessity to 
define laboratory markers for monitoring a bleeding ten-
dency was indicated. Such a model would obviously be 
valuable for evaluating the safety and efficacy of novel 
therapeutic regimens, 
Relation of Therapy, Bleeding Time 
Prolongation and Bleeding 
Effect of rt·PA. In the initial dose-finding phase, infusion 
of 15 ,ug/kg per min of rt-PA for 90 min (1.35 mg/kg total 
dose) caused only minimal prolongation of the mean bleed-
ing time associated with bleeding in only one dog. In 
contrast, extensive systemic fibrinogen degradation and sub-
stantial diminution of platelet aggregation ex vivo were 
observed with a fourfold higher dose (60 ,ug/kg per min). At 
the end of this infusion, the average bleeding time had 
increased more than sixfold over baseline values, with 
bleeding observed in two dogs. However, substantial rever-
sal of this prolongation occurred within 2 h after cessation of 
infusion unaccompanied by an increase in plasma fibrinogen 
levels or improvement in platelet aggregation, Thus, bleed-
ing time prolongation could not be attributed to induction of 
a systemic lytic state or altered platelet aggregability alone. 
Effect of aspirin and rt·PA. In contrast to the minor 
effects produced during separate administration, aspirin 
combined with rt-PA (15 ,ug/kg per min for 90 min) resulted 
in bleeding time values >30 min and recurrent continuous 
bleeding from previously coagulated wounds in five of six 
dogs. This prolongation was again reversed to a large extent 
2 h after the end of infusion. These results demonstrated a 
marked interactive effect of aspirin and rt-PA on bleeding 
and bleeding time prolongation and a highly significant 
relation between the occurrence of bleeding and bleeding 
time >9 min. 
Although bleeding time is generally recognized as the 
most basic overall test of platelet hemostatic function in 
vivo, its measurement and interpretation may be affected by 
problems of variability in part due to operator technique or 
intersubject differences in skin texture. Subjective analysis, 
particularly with respect to classification of bleeding and 
quantitation of bleeding time, may also have biased the 
initial phase of this study. Therefore, objective confirmation 
was obtained by a prospective randomized blinded study. 
For this phase, a single fixed dose of aspirin (15 mg/kg) 
was selected as the minimal requirement for achieving 
consistent platelet cyclooxygenase inhibition, confirmed by 
epinephrine-potentiated, arachidonic acid-induced platelet 
aggregation. A similar minimal dose was also required to 
inhibit aggregation in a previous rabbit study (24). Although 
substantially larger than that recommended for patients 
given thrombolytic therapy, this dose of aspirin is neverthe-
less less than the intravenous regimen (20 or 35 mg/kg) used 
to abolish platelet aggregation in previous canine studies 
(25,26). These results suggest the need for higher doses of 
aspirin to obtain platelet cyclooxygenase inhibition in dogs. 
Aspirin was then tested alone or in combination with an 
rt-PA dose (15 ,ug/kg per min for 90 min) at which only minor 
effects on bleeding frequency and prolongation of bleeding 
time were observed in the initial study group. This infusion 
rate produced plateau levels of rt-PA-related antigen in 
plasma approximately 50% of peak values observed in 
patients given rt-PA at the currently recommended 100 mg 
dose (27). 
Effect of aspirin and rt-PA on bleeding and bleeding time 
prolongation. The results obtained also demonstrated the 
marked interactive effect of aspirin and rt-PA on bleeding 
and bleeding time prolongation. The frequency of bleeding 
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was significantly greater in dogs receiving combined therapy 
than in those receiving rt-PA alone. In addition, bleeding 
time values >9 min correlated with bleeding with a sensitiv-
ity of 100% (all 9 dogs with bleeding had a bleeding time 
>9 min) and a specificity of 87% (14 of 16 dogs without 
bleeding had a bleeding time <9 min). Stepwise logistic 
regression, using a model that included variables of fibrin-
ogen concentration and bleeding time, excluded the possi-
bility that plasma fibrinogen measurement was a more sig-
nificantly predictive marker for bleeding. However, because 
of the unavailability of canine antiserum to measure fibrin-
ogen degradation products, the relation between bleeding 
frequency and fibrinogen degradation product elevation pro-
duced during thrombolytic infusion, as demonstrated in a 
previous clinical trial (28), could not be tested specifically in 
the present study. Taken together, these observations sug-
gest that bleeding time determination may provide a useful 
quantitative end point for the bleeding tendency associated 
with thrombolytic infusion and adjunctive antiplatelet ther-
apy. 
Presumptive Mechanism, Reversibility and 
Antifibrinolytic Therapy 
The possibility that barbiturate anesthesia may have 
induced slight platelet dysfunction affecting control bleeding 
times or ADP-induced platelet aggregation ex vivo (29) 
cannot be discounted. However, the similar response of the 
template bleeding time to the combination of rt-PA and 
aspirin in dogs and patients with acute myocardial infarction 
suggests that its influence on platelet function in vivo is 
minimal. 
Role of combined aspirin and rt·PA therapy. Similar 
increases in bleeding time were observed at 90 min in the 
initial dose-finding study with either 60 JLg/kg per min of 
rt-PA alone or the combination of aspirin and 15 JLg/kg per 
min of rt-PA, but prolongation occurred earlier and was 
more persistent in the latter group. Bleeding was also more 
frequent in the groups receiving combined administration of 
rt-PA and aspirin than in those receiving either agent alone, 
indicating that it may result primarily from an interactive 
effect of aspirin and rt-PA. Thus, it is likely that both the 
mechanism and extent of bleeding time prolongation are 
important in producing the bleeding tendency. These results 
also suggest that prolongation of the template bleeding time 
may be a more reliable marker of hemorrhagic tendency 
when agents affecting both the coagulation protein and 
platelet components of hemostasis are given in combination. 
Role of interference with formation of the hemostatic plug. 
Although its origin remains unclear, shortening of the bleed-
ing time observed after cessation of rt·PA infusion together 
with resolution of bleeding in six of nine randomized dogs 
argue against slowly reversible processes that might be 
related, for example, to degradation of plasma coagulation 
proteins or platelet membrane receptors. The transient na-
ture of these phenomena suggests instead that bleeding may 
primarily be due to a reversible interference with formation 
of the hemostatic plug. This hypothesis is further supported 
by the immediate reversal of bleeding and bleeding time 
prolongation with aprotinin, a serine protease inhibitor with 
potent antiplasmin activity (30). Reversibility of bleeding 
time prolongation induced by rt-PA and aspirin with a bolus 
injection of recombinant plasminogen activator inhibitor has 
been recently reported in a rabbit model (31). Thus, inter-
ference of hemostatic plug formation by plasmin generated 
during the course of thrombolytic infusion is the most 
obvious explanation for the occurrence of bleeding events in 
this study. Instability of the hemostatic plug due to de-
creased interdigitation of platelets after aspirin administra-
tion (32) may have initially impaired hemostasis, producing a 
predisposition to renewed bleeding after the start of throm-
bolytic therapy. 
Aprotinin as an antidote. Our findings indicate that ad-
ministration of an antifibrinolytic agent may be an effective 
antidote to life-threatening bleeding associated with throm-
bolytic therapy. Indeed, aprotinin has been successfully 
used to reduce blood loss associated with cardiac surgery 
(33,34), even after recent aspirin ingestion (35). However, its 
safety and efficacy in patients receiving thrombolytic infu-
sion require further investigation. 
Effect on surgical wounds. In a previous study (23) in 
which rt -PA was combined with aspirin, prolongation of the 
bleeding time was also observed, but this did not appear to 
predispose to excessive hemorrhage from surgical wounds. 
In that study, however, at the earliest, aspirin and rt-PA 
were given 1 h after completion of surgery, which possibly 
permitted normal hemostatic plug formation in the surgical 
wounds. 
Clinical Relevance and Future Studies 
In the present study, we did not investigate whether the 
dose ofrt-PA contributes to the bleeding tendency in dogs 
given aspirin. Such a contribution is, however, suggested by 
the results of the Thrombolysis in Myocardial Infarction 
(TIM I) II trial (10), which indicated that infusion of 150 mg 
of rt-PA was associated with a higher frequency of bleeding 
in patients given aspirin compared with the currently used 
100 mg dose. This study was also not designed to investigate 
whether bleeding may be prevented by controlling the bleed-
ing time, and this question can only be answered adequately 
in prospective trials with administration schemes that are 
modified on the basis of changes in the bleeding time. 
Because of its clinical application, the effect of heparin, 
which was not used in this study, on the bleeding tendency 
observed with the combination of aspirin and rt-PA needs to 
be evaluated in future studies. However, the already profuse 
and continuous nature of the hemorrhagic tendency ob-
served with combined therapy raises the potentially more 
relevant question of the efficacy of antifibrinolytic therapy in 
the setting of heparin anticoagulation. Finally, an appropri-
ate follow-up study would be to examine the effect of 
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streptokinase administration on bleeding time prolongation 
and frequency of bleeding in the present model. 
Whether the observed correlation between 1) bleeding 
time prolongation and bleeding, and 2) the interactive effect 
of aspirin and rt -P A on both the bleeding time and bleeding 
has significant clinical implications needs to be confirmed 
prospectively in large patient trials. This canine model may 
be particularly useful for investigation of alternative admin-
istration schemes of combined rt-PA/antiplatelet therapy not 
only in terms of thrombolytic potency, but also as related to 
bleeding tendency. In this context, the template bleeding 
time, which constitutes the first identified quantitative index 
for monitoring the bleeding tendency associated with throm-
bolytic therapy, may prove useful. 
We thank Lawrence W. Gimple, MD for helpful discussions and advice during 
the course of this study. 
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